Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Available from LipoScience is NMR (nuclear magnetic resonance) lipoprotein particle testing using the company’s Vantera clinical analyzer through Mayo Medical Laboratories. NMR lipoprotein testing on the Vantera analyzer will be accessible to Mayo Clinic physicians and patients and other hospital clients of Mayo Medical Laboratories.
Beckman Coulter Genomics’ BRAF assay has been granted clinical laboratory licenses in Pennsylvania, Maryland, Rhode Island, and Massachusetts. CLIA certification, plus licensure in those states, allows Beckman to accept clinical samples for genetic sequencing—the most technically complex CLIA category—and provide those results to physicians to use in treating, diagnosing, and preventing disease in patients.
IncellDx has reached an agreement with Kindstar Global to offer its proprietary laboratory test for the detection of oncogenic HPV E6, E7 mRNA in China. Kindstar is a large esoteric diagnostic testing business.
Quest Diagnostics has entered into a definitive agreement to acquire laboratory-related clinical outreach service operations of Dignity Health, a hospital system based in California. Under the agreement, Quest will acquire operations through which Dignity Health provides outreach diagnostic information services to patients and physician offices in parts of California and Nevada.
Quidel Corp. has completed its acquisition of BioHelix Corp. According to terms of the deal, Quidel will pay BioHelix shareholders $10 million in cash, plus additional amounts in connection with an R&D earn-out based on the completion of a designated number of assays and a commercial earn-out dependent on product sales over a defined period.
Applied Spectral Imaging and BioDot have entered into an agreement under which both companies will engage in combined sales and marketing of a product that will directly link ASI’s GenASIs imaging and analysis instrument and BioDot’s CellWriter automated dispensing system for FISH and karyotyping.
Meridian Bioscience has received FDA clearance for its Mycoplasma pneumoniae molecular diagnostic test on the Illumigene platform. By amplifying the specific DNA for the detection of M. pneumoniae, the test provides a definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner.
Beckman Coulter Life Sciences’ VersaComp antibody capture bead kits are designed to set compensation for multicolor flow cytometry experiments by allowing researchers to use the same reagents as they do in their experiments.
BioMérieux’s Labguard is a real-time wireless, automated, temperature-monitoring solution for hospitals, laboratories, blood banks, and pharmacies. The solution features real-time, 24/7 Web-based monitoring with alarm display and notifications via SMS, e-mail, and fax. The solution has sensor probes for different applications, including temperature, humidity, pressure, and other physical parameters.
DiaSorin’s Liaison IGF-1 assay is a solution for full automation of growth factor testing on a random-access analyzer, for accurately monitoring growth dysfunctions. The company offers an extensive menu of reliable, fully automated chemiluminescent assays suitable for endocrinology clinics, reference laboratories, hospitals, and physician office laboratories. Patients benefit from rapid and accurate results, and laboratories benefit from fast turnaround time and ease of use with the Liaison assay product portfolio.
